NasdaqCM - Delayed Quote USD

Aclarion, Inc. (ACONW)

Compare

0.0390

0.0000

(0.00%)

At close: November 29 at 9:30 AM EST

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA) BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology compa

GlobeNewswire 11 days ago

ACON
-0.55%
ACONW
0.00%
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help ...

ACCESSWIRE 18 days ago

ACON
-0.55%
ACONW
0.00%
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by

GlobeNewswire last month

ACON
-0.55%
ACONW
0.00%
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion”

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform, powered by a

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs Technology protected by 23 issued US patents, 17 issu

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...

ACCESSWIRE 2 months ago

DCGO

SOTK

CVKD
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology’s Role in Selecting Optimal Treatment Options BROOMFIELD, CO, Sept. 10, 2024 (GLOBE N

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Added to PRISM Emerging Medical Devices Index

Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Michigan's Sheridan Community HospitalPRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devi

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967 Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750 BROOMFIELD, CO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:

GlobeNewswire 2 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the loc

GlobeNewswire 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE in the Coming Months Adding Practical Real-world Data to Aclarion’s Expanding Body of Clinical Evidence BROOMFIELD, CO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary

GlobeNewswire 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Aclarion ( NASDAQ:ACON ) Second Quarter 2024 Results Key Financial Results Net loss: US$1.24m (loss narrowed by 16...

Simply Wall St. 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsu

GlobeNewswire 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Announces First Commercial Agreement in Michigan

Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor, and the Patients he Serves in Central Michigan BROOMFIELD, CO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identi

GlobeNewswire 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private Health Insurance in the Greater London Market now Have Access to Aclarion’s Nociscan. BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intellige

GlobeNewswire 3 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Market BROOMFIELD, CO, July 09, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain,

GlobeNewswire 4 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First Insurance Company to Approve Payment for Nociscan BROOMFIELD, CO, June 26, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify

GlobeNewswire 5 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging

GlobeNewswire 5 months ago

ACON
-0.55%
ACONW
0.00%
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution

Notice of Allowance is for the 23rd US Patent to be Awarded to AclarionNew Patent Allows Aclarion Exclusive Access to Enhanced Post-processing Techniques of Magnetic Resonance Spectroscopy (MRS) to Improve Data QualityAclarion's Patent Portfolio Cont...

NewMediaWire 5 months ago

ACON
-0.55%
ACONW
0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aclarion, Inc. (ACONW)

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Aclarion Added to PRISM Emerging Medical Devices Index

Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans

Aclarion Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aclarion Announces First Commercial Agreement in Michigan

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution